Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made […]
Read MorePancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made […]
Read MoreA couple of weeks back I wrote on the good fortune of Carvykti in Europe. Its marketing authorisation had been approved […]
Read MoreA couple of days ago (16th March 2024), GSK posted absolutely excellent data on their PD-1 drug Jemperli (dostarlimab) at a […]
Read MoreOutcomes from active surveillance have clearly shown that it is the optimal method of managing many early prostate cancers. Yet, […]
Read MoreOlder patients with classical Hodgkin lymphoma (cHL) require more effective and less toxic therapies than younger patients. In this multicenter, […]
Read MoreAdvancements in comprehending the biogenesis, dependencies, and mutational landscape of multiple myeloma dramatically expanded over the past two decades. This […]
Read MoreTumor metastasis involves cells migrating directionally in response to external chemical signals. Reactive oxygen species (ROS) in the form of […]
Read MoreWe sought to evaluate the prognostic impact of prostate-specific antigen (PSA) at 6 months after completion of radiotherapy (RT) in […]
Read MoreI said in my blog yesterday that we should rightly be excited about Pfizer’s bet on bispecifics and a week on […]
Read MoreAlthough germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in […]
Read MoreError: Contact form not found.